Core Viewpoint - Beijing Tianxing Medical Co., Ltd. has terminated its IPO on the Shanghai Stock Exchange's Sci-Tech Innovation Board due to the withdrawal of its sponsor, as per the relevant regulations [1] Company Overview - Tianxing Medical is an innovative medical device company specializing in sports medicine, focusing on the research, production, and sales of sports medicine implants, active devices, consumables, and surgical tools [1] - As of September 30, 2024, the company has established a complete matrix of 47 approved sports medicine products, including several first domestically approved products in the implant field [1] Market Position - The company has built a strong brand presence in the sports medicine sector, covering over 3,000 hospitals across 31 provinces, autonomous regions, and municipalities [2] - In 2023, Tianxing Medical held approximately 4% of the Chinese sports medicine medical device market, ranking first among domestic companies [2] Financial Performance - The company reported revenues of approximately CNY 73.01 million, CNY 148 million, CNY 241 million, and CNY 223 million for the years 2021, 2022, 2023, and the first nine months of 2024, respectively [2] - Net profits for the same periods were approximately CNY -110 million, CNY 40.34 million, CNY 63.58 million, and CNY 64.08 million [2] Financial Metrics - As of September 30, 2024, total assets amounted to CNY 550.99 million, with equity attributable to shareholders of CNY 446.13 million [3] - The company's asset-liability ratio was 16.20% as of September 30, 2024, showing a decrease from previous years [3] - The net profit attributable to shareholders was CNY 6.41 million for the first nine months of 2024, with a basic earnings per share of CNY 1.38 [4] Investment Plans - The total amount of funds raised will be used entirely for projects related to the company's main business, including a smart factory project in Suzhou and product research and development [2]
天星医疗上交所科创板IPO终止 公司产品已覆盖医院超过3000家
智通财经网·2025-06-06 11:33